Business
HempTech (HTCO) to Buildout Drug Development & Manufacturing Facility for Biotica Pharmaceuticals - HempTech's Automation Technology Help Grow Pharma Grade Strains in 2017
HempTech (HTCO) to Buildout Drug Development & Manufacturing Facility for Biotica Pharmaceuticals - HempTech's Automation Technology Help Grow Pharma Grade Strains in 2017.
About this update from Music Licensing, Inc.
[{"type":"text","content":"\n \n \n HempTech (HTCO) to Buildout Drug Development & Manufacturing Facility for Biotica Pharmaceuticals - HempTech's Automation Technology Help Grow Pharma Grade Strains in 2017\n \n \nHempTech (HTCO) to Buildout Drug Development & Manufacturing Facility for Biotica Pharmaceuticals - HempTech's Automation Technology Help Grow Pharma Grade Strains in 2017\n \n ST. PETERSBURG, FL--(Marketwired - Dec 28, 2016) - HempTech Corp. (OTC PINK: HTCO), a provider of advanced Controlled Environment Agriculture (CEA) with sophisticated automation and analytical tools for the cultivators of legal industrial hemp and marijuana, has agreed to buildout drug development and manufacturing facility, one of many, for Biotica Pharmaceuticals beginning second quarter 2017. The new drug development and manufacturing facility will contain; Grow, Lab Extraction and Laboratory. HempTech will use its most sophisticated grow system, the grow.droid, in conjunction with CognetiX for development and delivery of pharmaceutical grade strains for use of medical discovery by Biotica. HempTech is the only cannabis grow technology provider offering advanced CEA and sophisticated analytics for development of pharmaceutical grade marijuana strains for pharmaceuticals globally.\n Biotica Pharmaceuticals has developed BPRx™ Technology, which is a novel combinatorial library of phytocannabinoids and endocannabinoids for treating various human diseases. Biotica's current technology includes;\n \n \n BPRx™-060216: Lead drug candidate to treat Eosinopilic Esophagitis (EoE)\n \nBPRx™-060234: Lead drug candidate to treat early stages of Alzheimer's disease\n \n \n \n \n Biotica, a privately held pharmaceutical company, has applied for two world-wide patent rights for the platform technologies and for specific novel drug formulations. They are actively procuring a portfolio of patents, trademarks, and trade secrets to reinforce and protect their technologies. They are conducting discovery research both in-house and with joint development agreements using their platform technology. For more information, you can visit their website at: http://www.bioticapharma.com.\n \"We are on mark to have an amazing year in 2017; from long expected sales on our renown product categories, major agreements such as with Biotica, to joint ventures and partnerships wit...